2010
DOI: 10.1111/j.1365-2036.2010.04466.x
|View full text |Cite
|
Sign up to set email alerts
|

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

Abstract: SUMMARY BackgroundAdalimumab induces and maintains remission in adults with Crohn's disease.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

7
123
3
8

Year Published

2011
2011
2021
2021

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 170 publications
(141 citation statements)
references
References 41 publications
7
123
3
8
Order By: Relevance
“…However, they failed to report the improvement recorded during the first 12 months of treatment, which reached 0.135 in our sample. Other studies, using different instruments for measuring quality of life, obtained findings consistent with ours in terms of quality of life improvement (30,32).…”
Section: After One Year Of Treatment With Adalimumabsupporting
confidence: 90%
See 1 more Smart Citation
“…However, they failed to report the improvement recorded during the first 12 months of treatment, which reached 0.135 in our sample. Other studies, using different instruments for measuring quality of life, obtained findings consistent with ours in terms of quality of life improvement (30,32).…”
Section: After One Year Of Treatment With Adalimumabsupporting
confidence: 90%
“…These results in the multicenter study CARE (20) are 9.6%, 17.3% and 18.4% respectively. The most striking finding of our results, in relation to these previous studies, is the value of absenteeism at baseline (32%) versus 15% in CHOICE (30) and 23% in CARE (20). These variations may be explained away by the different work environments in the different countries where the studies were carried out, as well as by differences in patient profiles.…”
Section: After One Year Of Treatment With Adalimumabsupporting
confidence: 71%
“…LOR occurs in a significant fraction of patients and has been reported to occur in about 20-50% of patients within the first year of therapy 5,23 . Switching anti-TNF has been shown to be an effective strategy in case of LOR and drug intolerance [24][25][26][27] but should be omitted simply for the reason of a more convenient route of drug administration 28 . Even after failure of two anti-TNF agents, there may be considerable rates of response and remission using a third one 29 .…”
Section: Introductionmentioning
confidence: 99%
“…At baseline 88 patients (13%) had at least one draining cutaneous fistula. Complete fistula healing was achieved by 34 patients (39%) at the last visit (dates from week 4 to week 36) [Lichtiger et al 2010]. Improvements in quality of life and work productivity were sustained all throughout, as well as the group of non-responders.…”
Section: Adalimumabmentioning
confidence: 93%